bet体育(365·China官网)正规-APP下载IOS
CN
About Ribo
About Ribo
International R&D Center
Scientific Advisory Board
Our Culture
News
Science
About Oligonucleotide Therapeutics
Technological Innovations
Intellectual Property
Pipeline
Pipeline
Products
Clinical Trials
Collaboration
BD and Collaboration
Investors
Overview
Careers
Our Culture
Career Development
Recruitment
About Ribo
Science
Pipeline
Collaboration
Investors
Careers
About Ribo
International R&D Center
Scientific Advisory Board
Our Culture
News
About Oligonucleotide Therapeutics
Technological Innovations
Intellectual Property
Pipeline
Products
Clinical Trials
BD and Collaboration
Overview
Our Culture
Career Development
Recruitment
CN
Search
News
About Ribo
International R&D Center
Scientific Advisory Board
Our Culture
News
About Ribo
News
Ribo was selected as one of 2019 "Most Innovative Pharmaceutical Companies in Asia" by Clarivate Analytics
Sep 03,2019
Last : Ribo completed the enrollment of the first patient into the Chinese phase II clinical trial on ASOISIS449884 Injection
Next : Ribo's clinical application for new oligonucleotide therapeutics in the treatment of type 2 diabetes got approved
Sep 03,2019
